These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 16258881)
1. The detection of quantitative serum p53 protein in lung cancer. Sen E; Gönüllü U; Akar N Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881 [TBL] [Abstract][Full Text] [Related]
2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916 [TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibodies: predictors of survival in small-cell lung cancer? Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647 [TBL] [Abstract][Full Text] [Related]
5. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133 [TBL] [Abstract][Full Text] [Related]
6. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237 [TBL] [Abstract][Full Text] [Related]
7. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival. Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333 [TBL] [Abstract][Full Text] [Related]
8. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer. Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907 [TBL] [Abstract][Full Text] [Related]
9. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117 [TBL] [Abstract][Full Text] [Related]
10. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451 [TBL] [Abstract][Full Text] [Related]
12. [The value of serum tumor marker in the diagnosis of lung cancer]. Shi GL; Hu XL; Yue SD; Song CX Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768 [TBL] [Abstract][Full Text] [Related]
14. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)]. Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076 [TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer. Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341 [TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560 [TBL] [Abstract][Full Text] [Related]
20. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]